Research graph
References from HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL. Local targets link to admitted publications; unresolved targets remain external evidence.
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)
10.1200/jco.2020.38.15_suppl.8057 · 2020 · External reference
Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy
10.1111/bjh.17662 · 2021 · External reference
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
10.1038/s41408-024-01119-2 · 2024 · External reference
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
10.1182/bloodadvances.2022008893 · 2023 · External reference
Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma
10.1182/bloodadvances.2021005020 · 2021 · External reference
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
10.1182/blood.2021011898 · 2021 · External reference
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
10.1038/nrclinonc.2017.148 · 2018 · External reference
CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial
10.1200/jco.19.03279 · 2020 · External reference
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome
10.1016/j.jtct.2023.03.006 · 2023 · External reference
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
10.1002/pbc.21423 · 2008 · External reference
Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL
10.1200/jco.21.01405 · 2022 · External reference
Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report
10.1200/jco.20.03585 · 2022 · External reference
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results
10.1038/s41375-024-02220-y · 2024 · External reference
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
10.1056/nejmoa1709866 · 2018 · External reference
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
10.1136/jitc-2025-011549 · 2025 · External reference
Neurotoxicity after CTL019 in a pediatric and young adult cohort
10.1002/ana.25315 · 2018 · External reference
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling
10.1038/s41409-025-02679-y · 2025 · External reference
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel
10.1182/bloodadvances.2025016824 · 2025 · External reference
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
10.1182/bloodadvances.2022007423 · 2023 · External reference
Cytokine-mediated CAR T therapy resistance in AML
10.1038/s41591-024-03271-5 · 2024 · External reference
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
10.1038/s41467-021-21168-6 · 2021 · External reference
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
10.1136/jitc-2025-012401 · 2025 · External reference
Patients with deleterious germline variants in STXBP2 develop toxicity after CAR-T cell therapy with axicabtagene ciloleucel
10.1182/blood-2022-166322 · 2022 · External reference
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
10.1016/j.celrep.2017.04.031 · 2017 · External reference
